Evidence Review
Perimenopause: Hot Flashes, Mood, and Estradiol
Mahajan et al. (2025) conducted a randomized, double-blind, placebo-controlled trial in 80 perimenopausal women (73 completed per-protocol). Participants received Shatavari root extract or placebo for 8 weeks [1]. The primary outcome, the Menopause Rating Scale (MRS) total score, showed a mean reduction of 12.54 points in the Shatavari group versus 1.61 points in the placebo group (p < 0.0001). Hot flash frequency fell by 3.84 events per day in the treatment group versus 1.03 in controls (p = 0.002). Perceived stress (PSS-10) improved by 7.11 points in the Shatavari group versus a deterioration of 3.81 points in placebo (p < 0.0001). Serum estradiol increased significantly in the treatment group (p = 0.003), providing a mechanistic anchor for the symptom improvements. No adverse events were recorded.
Gudise et al. (2024) conducted an 8-week multicenter RCT in 70 menopausal women (35 per arm) [2]. The Utian Quality of Life (UQoL) total score increased by 35.13% in the Shatavari group versus minimal change in placebo (p < 0.0001). Hot flashes fell from a mean of 1.97 to 0.14 episodes per day in the treatment group versus 2.0 to 1.18 in placebo. Night sweats dropped from 0.77 to 0.06 per day in active subjects. Insomnia scale scores improved 41% with Shatavari versus a 19.56% increase (worsening) in the placebo group. Depression, anxiety, and stress scores all significantly improved (all p < 0.0001). Adverse events were mild and infrequent.
Together these trials provide converging evidence at two stages of hormonal transition, though both used the same root extract standardization and involved relatively small samples. Independent replication with larger cohorts is warranted.
Lactation: Prolactin and Infant Outcomes
Gupta and Shaw (2011) conducted a double-blind RCT in 60 lactating women (30 per group, mean age 25.6 years, infants averaging 2.8 months old) [3]. The Shatavari group showed a mean 32.87% increase in serum prolactin versus 9.56% in controls — approximately a threefold difference. Infant weight gain was 16.13% in the treatment group versus 5.68% in controls. Maternal satisfaction scores improved 1.54 points with Shatavari versus 0.48 points in controls. Infant well-being ratings similarly diverged significantly. All differences reached p < 0.05.
Sharma et al. (1996), in an earlier RCT, corroborated the lactation benefit, finding improved milk volumes and breast fullness times in mothers receiving Shatavari extract compared to placebo [6]. A 2025 RCT by Ajgaonkar et al. further replicated the postpartum lactation benefit with modern study design [4], suggesting the prolactin-elevating effect is robust across populations and formulations.
The proposed mechanism is stimulation of prolactin secretion via phytoestrogenic and dopaminergic pathways, though the precise receptor-level action has not been fully characterized in humans.
Adaptogenic Mechanisms
A 2023 narrative review by Singh et al. synthesized animal and clinical data on Shatavari's adaptogenic properties [5]. The authors describe modulation of the HPA axis with suppression of stress-induced cortisol excess, upregulation of BDNF (brain-derived neurotrophic factor) supporting neuroplasticity, and enhancement of antioxidant enzyme activity (SOD, GSH peroxidase, catalase) across brain regions. GABAergic and serotonergic modulation were highlighted as likely contributors to the anxiolytic and antidepressant effects observed in animal models.
Human clinical data on pure stress adaptation (outside the perimenopausal studies) is more limited, though enzyme-treated asparagus extract (a related preparation) has shown anti-stress and sleep quality benefits in small controlled trials. The animal data appears mechanistically consistent with the human hormonal studies, but head-to-head comparisons with well-validated adaptogens like ashwagandha are not yet available.
Overall Evidence Assessment
The evidence for Shatavari's effects on lactation is moderately strong, supported by multiple independent RCTs across decades. The evidence for perimenopausal and menopausal symptom relief is promising, with two recent well-designed trials showing large effect sizes, though independent replication is still needed. The adaptogenic and stress-modulation evidence is mainly mechanistic and animal-based, with human data limited to secondary outcomes in hormonal trials. For women navigating perimenopause or supporting breastfeeding, Shatavari represents a well-tolerated option with a credible evidence base.